Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Pharmacoeconomics
|
May 5, 2025
A Framework for Reliable, Transparent, and Reproducible Population-Adjusted Indirect Comparisons
K Jack Ishak, Conor Chandler, Fei Fei Liu, et al.
Clinical Therapeutics
|
October 3, 2017
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States
Christopher G Pelligra, Kejal Parikh, Shien Guo, et al.
Journal of Market Access & Health Policy
|
June 14, 2021
Modeling long-term health and economic implications of new treatment strategies for Parkinson's disease: an individual patient simulation study
Conor Chandler, Henri Folse, Peter Gal, et al.
Plos One
|
April 12, 2023
Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data
Lisa J McGarry, Zahra Bhaiwala, Andrea Lopez, et al.
Journal of Medical Economics
|
July 28, 2023
Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan
Conor Chandler, Heather Burnett, Kassandra Schaible, et al.
Clinical Lung Cancer
|
September 5, 2024
Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons
Christine Garcia, Devin Abrahami, Anna Polli, et al.
Therapeutic Advances in Respiratory Disease
|
February 27, 2019
Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor
Jaime L Rubin, Lasair O'Callaghan, Christopher Pelligra, et al.
Journal of Comparative Effectiveness Research
|
December 15, 2025
Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison
Todd Bauer, Devin Abrahami, Anna Polli, et al.
Future Oncology (London, England)
|
October 26, 2023
Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated <i>EGFR</i> Exon 20 insertion-mutated non-small-cell lung cancer
Tae Min Kim, Nicolas Girard, Natasha B Leighl, et al.
Targeted Oncology
|
November 3, 2025
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study
Rachel E Sanborn, Caicun Zhou, Ke-Jing Tang, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Pharmacoeconomics
|
May 5, 2025
A Framework for Reliable, Transparent, and Reproducible Population-Adjusted Indirect Comparisons
K Jack Ishak, Conor Chandler, Fei Fei Liu, et al.
Clinical Therapeutics
|
October 3, 2017
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States
Christopher G Pelligra, Kejal Parikh, Shien Guo, et al.
Journal of Market Access & Health Policy
|
June 14, 2021
Modeling long-term health and economic implications of new treatment strategies for Parkinson's disease: an individual patient simulation study
Conor Chandler, Henri Folse, Peter Gal, et al.
Plos One
|
April 12, 2023
Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data
Lisa J McGarry, Zahra Bhaiwala, Andrea Lopez, et al.
Journal of Medical Economics
|
July 28, 2023
Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan
Conor Chandler, Heather Burnett, Kassandra Schaible, et al.
Clinical Lung Cancer
|
September 5, 2024
Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons
Christine Garcia, Devin Abrahami, Anna Polli, et al.
Therapeutic Advances in Respiratory Disease
|
February 27, 2019
Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor
Jaime L Rubin, Lasair O'Callaghan, Christopher Pelligra, et al.
Journal of Comparative Effectiveness Research
|
December 15, 2025
Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison
Todd Bauer, Devin Abrahami, Anna Polli, et al.
Future Oncology (London, England)
|
October 26, 2023
Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated <i>EGFR</i> Exon 20 insertion-mutated non-small-cell lung cancer
Tae Min Kim, Nicolas Girard, Natasha B Leighl, et al.
Targeted Oncology
|
November 3, 2025
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study
Rachel E Sanborn, Caicun Zhou, Ke-Jing Tang, et al.
Page
of 1